[go: up one dir, main page]

NO20013160L - Kombinasjoner av ileal gallesyretransport-inhibitorer og nikotinsyrederivater for kardiovaskulore indikasjoner - Google Patents

Kombinasjoner av ileal gallesyretransport-inhibitorer og nikotinsyrederivater for kardiovaskulore indikasjoner

Info

Publication number
NO20013160L
NO20013160L NO20013160A NO20013160A NO20013160L NO 20013160 L NO20013160 L NO 20013160L NO 20013160 A NO20013160 A NO 20013160A NO 20013160 A NO20013160 A NO 20013160A NO 20013160 L NO20013160 L NO 20013160L
Authority
NO
Norway
Prior art keywords
combinations
transport inhibitors
ileal bile
cardiovascular indications
acid derivatives
Prior art date
Application number
NO20013160A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013160D0 (no
Inventor
Bradley T Keller
Kevin C Glenn
Daniel T Connolly
Original Assignee
Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26811675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20013160(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle Llc filed Critical Searle Llc
Publication of NO20013160D0 publication Critical patent/NO20013160D0/no
Publication of NO20013160L publication Critical patent/NO20013160L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20013160A 1998-12-23 2001-06-22 Kombinasjoner av ileal gallesyretransport-inhibitorer og nikotinsyrederivater for kardiovaskulore indikasjoner NO20013160L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11395598P 1998-12-23 1998-12-23
US14255099P 1999-07-07 1999-07-07
PCT/US1999/027950 WO2000038729A1 (en) 1998-12-23 1999-12-17 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications

Publications (2)

Publication Number Publication Date
NO20013160D0 NO20013160D0 (no) 2001-06-22
NO20013160L true NO20013160L (no) 2001-08-21

Family

ID=26811675

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013160A NO20013160L (no) 1998-12-23 2001-06-22 Kombinasjoner av ileal gallesyretransport-inhibitorer og nikotinsyrederivater for kardiovaskulore indikasjoner

Country Status (25)

Country Link
US (1) US20030125316A1 (zh)
EP (1) EP1140191B1 (zh)
JP (1) JP2002533415A (zh)
KR (1) KR20010102963A (zh)
CN (1) CN1338946A (zh)
AR (1) AR037806A1 (zh)
AT (1) ATE226448T1 (zh)
AU (1) AU776952B2 (zh)
BR (1) BR9916567A (zh)
CA (1) CA2356664A1 (zh)
CZ (1) CZ20012343A3 (zh)
DE (1) DE69903661T2 (zh)
DK (1) DK1140191T3 (zh)
EA (1) EA005030B1 (zh)
ES (1) ES2188285T3 (zh)
HK (1) HK1044472A1 (zh)
HU (1) HUP0104593A3 (zh)
IL (1) IL143938A0 (zh)
MX (1) MXPA01006467A (zh)
MY (1) MY121399A (zh)
NO (1) NO20013160L (zh)
NZ (1) NZ512533A (zh)
PL (1) PL348581A1 (zh)
PT (1) PT1140191E (zh)
WO (1) WO2000038729A1 (zh)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
ME00145B (me) 2001-01-26 2010-10-10 Merck Sharp & Dohme Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
WO2003022286A1 (en) 2001-09-08 2003-03-20 Astrazeneca Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
ES2272776T3 (es) 2001-09-21 2007-05-01 Schering Corporation Tratamiento de xantomas con derivados de azetidinona como inhibidores de la absorcion de esterol.
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
SI3023102T1 (sl) 2010-11-04 2018-11-30 Albireo Ab IBAT inhibitorji za zdravljenje jetrnih bolezni
CN103228270B (zh) * 2010-11-08 2016-02-10 阿尔比里奥公司 含ibat抑制剂和胆汁酸结合剂的药物组合
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
PT2861229T (pt) * 2012-06-15 2021-01-05 Conaris Res Institute Ag Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
WO2015199147A1 (ja) 2014-06-25 2015-12-30 味の素株式会社 固形製剤及びその着色防止又は着色低減方法
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
ES2874546T3 (es) 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
WO2019032026A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE GRANULES, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
WO2019234077A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES3011850T3 (en) 2018-06-20 2025-04-08 Albireo Ab Crystal modifications of odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CN118834175A (zh) 2019-02-06 2024-10-25 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
CA3127568A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
TWI865673B (zh) 2019-12-04 2024-12-11 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114786772B (zh) * 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
JP7695242B2 (ja) 2019-12-04 2025-06-18 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
TWI871392B (zh) 2019-12-04 2025-02-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
JP7665620B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CA3198216A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US20230398125A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
MY121399A (en) 2006-01-28
DK1140191T3 (da) 2003-02-24
MXPA01006467A (es) 2004-03-10
DE69903661T2 (de) 2003-07-03
DE69903661D1 (de) 2002-11-28
EP1140191B1 (en) 2002-10-23
EP1140191A1 (en) 2001-10-10
US20030125316A1 (en) 2003-07-03
HK1044472A1 (zh) 2002-10-25
ATE226448T1 (de) 2002-11-15
EA200100703A1 (ru) 2001-12-24
CN1338946A (zh) 2002-03-06
KR20010102963A (ko) 2001-11-17
JP2002533415A (ja) 2002-10-08
PL348581A1 (en) 2002-06-03
NZ512533A (en) 2004-02-27
AU776952B2 (en) 2004-09-30
NO20013160D0 (no) 2001-06-22
BR9916567A (pt) 2001-12-11
CZ20012343A3 (cs) 2001-12-12
IL143938A0 (en) 2002-04-21
AR037806A1 (es) 2004-12-09
HUP0104593A3 (en) 2004-10-28
AU2348100A (en) 2000-07-31
HUP0104593A2 (hu) 2002-03-28
CA2356664A1 (en) 2000-07-06
WO2000038729A1 (en) 2000-07-06
EA005030B1 (ru) 2004-10-28
PT1140191E (pt) 2003-01-31
ES2188285T3 (es) 2003-06-16

Similar Documents

Publication Publication Date Title
NO20013160L (no) Kombinasjoner av ileal gallesyretransport-inhibitorer og nikotinsyrederivater for kardiovaskulore indikasjoner
DK1140189T3 (da) Kombinationer af ileal galdesyre-transportinhibitorer og fibrinsyrederivater til cardiovaskulære indikationer
NO20013159L (no) Kombinasjoner av ileumgallesyretransportinhibitorer og gallesyresekvestreringsmidler for kardiovaskulore indikasjoner
HUP0201972A3 (en) Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
NO20010016D0 (no) Benzotiepiner med aktivitet som inhibitorer for ileal gallesyretransport og opptak av taurocholat
NO20012103L (no) Fremgangsmåte for transportering og installering av et ekspanderbart stålrör
NO20021082D0 (no) Anordning for og en fremgangsmåte ved forankring av en ekspanderbar rörledning
NO20014823D0 (no) Heterocyklus-holdige bifenyl-aP2-inhibitorer og metode
NO982176D0 (no) Korrosjonsinhiberte organiske syresammensetninger og fremgangsmÕter for anvendelse av disse
PL366338A1 (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
NO991247L (no) Prosjektil og framgangsmaate for aa tilvirke et slikt
NO20002614D0 (no) Internet-hurtiglagringssystem og fremgangsmÕte og arrangement i et slikt system
NO984563D0 (no) FremgangsmÕte og blanding for inhibering av korrosjon
NO20006394L (no) Fremgangsmåte og anordning for bestemmelse av tilgang til et skjult mål
NO20002724L (no) Metode og utstyr for ikke-destruktiv inspeksjon av objekter basert på halografisk interferometri
NO982177D0 (no) Metallkorrosjonsinhiberte organiske syresammensetninger og fremgangsmÕter for anvendelse av disse
NO20012293D0 (no) Utvidbar stent og fremgangsmåte for fremstilling
NO995564L (no) Fremgangsmåte og konstruksjon for inhibisjon av cellemigrering
NO20014627D0 (no) Lastearrangement og fremgangsmåte for overföring av godsenheter
NO995416D0 (no) Fremgangsmåte og utstyr for testing av legemer
NO994228D0 (no) Metode og innretning for telling av celler i urin
NO20001447D0 (no) Modifisert polyasparginsyre og fremgangsmåte for produksjon og bruk derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application